GRFS — Grifols S.A.
$5.2B market cap · 5 upcoming readouts tracked
Clinical trial readout dates for Grifols S.A., compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
The next expected readout is September 2027 .
Next readout September 2027 in ~10 months
Upcoming readouts 5 5 Phase 3
Market cap $5.2B
Upcoming readouts Phase 3 Alpha-1 15% September 2027Recruiting
Phase 3 Gamunex-C CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) ·
NCT07540221 December 2027Recruiting
Phase 3 Gamunex-C, 10% Injectable Solution Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma ·
NCT07582432 August 2028Recruiting
Phase 3 Alpha-1 MP Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency ·
NCT02796937 September 2028Enrolling
Phase 3 Xembify Hypogammaglobulinemia; Bacterial Infections ·
NCT05645107 August 2029Recruiting
Companies working on similar indications CRSP CRISPR Therapeutics AGantitrypsin, alpha, hodgkin NRIX Nurix Therapeutics Inc.lymphocytic, leukemia, lymphoma ARGX argenx SEcidp, demyelinating, inflammatory KYKOF Kyowa Kirin Co. Ltd.hodgkin, leukemia, lymphoma IBRX ImmunityBio Inc.hodgkin, lymphoma ADPT Adaptive Biotechnologies Corporationmyeloma, multiple
Discussion No messages yet. If you follow GRFS, you can start the conversation.
Track GRFS in real time
See live implied volatility for
GRFS and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on GRFS
Trial data from ClinicalTrials.gov
(U.S. National Library of Medicine); filings and reported financials from
SEC EDGAR — U.S. government
works in the public domain. Dates are study-reported primary completion dates,
which routinely shift and are not results-release dates. Information only, not
investment advice.